Six-year data demonstrate a durable disease-modifying effect of ProTrans in type 1 diabetes

• Durable effect ≥6 years
• Approximately 50% of insulin-producing function preserved
• Strategy confirmed: a single infusion may be sufficient for clinical efficacy

Previously reported long-term data up to five years demonstrated that ProTrans-treated patients, at the group level, preserved approximately 60% of their endogenous insulin production, compared with around 15% with placebo treatment. The six-year follow-up demonstrates that this clinically meaningful separation is maintained, with ProTrans-treated patients continuing to retain around half of their baseline insulin production at the group level, years after receipt of treatment.

In the placebo arm, endogenous insulin production was, as expected with disease progression, largely lost earlier, and at this late time point the number of patients completing long-term follow-up is therefore limited. The Company therefore considers the six-year data to primarily reflect durability of treatment response, rather than to serve as a basis for further quantitative group-level comparisons.

“After six years of follow-up, all patients treated with ProTrans retain higher endogenous insulin production than any patient in the placebo group. This pattern has been consistent since three years post-treatment, without any observed differences in adverse events between the groups,” says Mathias Svahn, CEO of NextCell.

In light of the clear and sustained clinical effect, the Company intends to advance ProTrans toward market approval as a single-infusion treatment for type 1 diabetes. In parallel, NextCell continues to develop ProTrans with the aim of further enhancing and prolonging the treatment effect through repeated infusions, which are being evaluated in the ongoing ProTrans-Repeat study. Results from ProTrans-Repeat, including follow-up data up to seven years, are expected to be reported shortly.